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Abbreviations
1-MT  1-Methyl-tryptophan
Cas  CRISPR associated system
CRISPR  Clustered regularly interspaced short palindro-
mic repeats
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase
LacNAc  Lectin-inhibitor N-acetyl-d-lactosamine
LAG-3  Lymphocyte-activation gene 3
MLTC  Mixed lymphocyte tumor culture(s)
RT-qPCR  Quantitative reverse transcription polymerase 
chain reaction
Treg  Regulatory T cell
TSN  Tumor-derived cell culture supernatants
Introduction
Melanoma, the most aggressive form of skin cancer, has 
long been recognized as a highly immunogenic tumor and a 
good target for immunotherapy [1]. High densities of differ-
ent types of infiltrating immune cells have been correlated 
with increased (e.g., CD8 T cells) or worse (e.g., regula-
tory T cells) survival [2, 3]. Infusion of ex vivo-expanded 
tumor-reactive T cells resulted in objective tumor responses 
in metastatic melanoma patients [4, 5]. We showed that 
generation of T cell batches for infusion by weekly stim-
ulation of peripheral blood mononuclear cells (PBMC)-
derived T cells in mixed lymphocyte autologous tumor cell 
cultures (MLTC) leads to the expansion of high numbers 
of tumor-reactive T cells [5]. In depth, analysis of these 
tumor-reactive T cells showed that in selected cultures up 
to 80% of CD8 T cells highly selectively recognize autolo-
gous tumors and show very limited reactivity against HLA-
matched melanoma cell lines and known shared antigens 
[6, 7]. However, for a number of patients, multiple MLTC 
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were needed to obtain the required amount of T cells for 
infusion, suggesting that one or more tumor intrinsic or 
extrinsic factors negatively affect the activation of tumor-
specific T cells [5].
Several tumor cell intrinsic factors have been found to 
hamper T cell immunity, including the expression of check-
point receptors, the expression and secretion of galectins, 
or indoleamine 2,3-dioxygenase (IDO) [8–11]. The immu-
nosuppressive effects of galectin-3 and galectin-1 are most 
often described [12–14]. Galectin-1 induces the differen-
tiation of immunoregulatory, IL-10 producing Th cells 
[15], whereas galectin-3 can hamper T cell activation by 
interfering with T-cell receptor signaling [16] and by bind-
ing to the checkpoint inhibitor LAG-3 [17]. Additionally, 
both galectin-1 and galectin-9 have been shown to increase 
apoptosis in T cells [18–21].
IDO is a well-known tumor-expressed molecule 
involved in immunosuppression and tolerance [9]. It cata-
lyzes the rate-limiting first step in tryptophan catabolism 
[22] and thereby directly affects T cell proliferation due to 
tryptophan starvation [23]. In addition, the metabolites of 
tryptophan have a toxic effect on T cells. Furthermore, IDO 
may induce and sustain regulatory T cells (Tregs) [24, 25], 
which in turn may hamper efficient generation of tumor-
reactive T cells [26, 27]. In the human setting, Tregs have 
been shown to suppress the expansion of tumor-associated 
antigen-specific T cells [27, 28] even in a melanoma anti-
gen-specific manner [29, 30].
The objective of this study was to identify factors nega-
tively affecting the expansion of tumor-reactive T cells 
and means to neutralize their effect in our clinical, GMP-
compliant protocol to generate tumor-reactive T cells for 
use in adoptive cell transfer (ACT). Here, we show that co-
expansion of  CD4+CD25hiFoxP3+ T cells and/or tumor cell 
produced IDO and galectin-3 during MLTC have a negative 
impact on the activation and expansion of tumor-specific T 
cells, and we describe different manners to circumvent this.
Materials and methods
Mixed lymphocyte tumor cultures
Tumor-reactive T cells were generated using mixed lym-
phocyte tumor cultures (MLTC) using a protocol that was 
successfully applied previously for generation of tumor-
reactive T cells [7, 31]. In brief, cryopreserved PBMC were 
thawed and co-cultured with irradiated, autologous tumor 
cells in a ratio of [10:1] in Iscove’s MDM (Lonza, Verviers, 
Belgium) supplemented with 8% heat-inactivated pooled 
human serum (Sanquin Bloodbank), l-glutamine (4 mM), 
penicillin (50  U/ml), and streptomycin (50  µg/ml) (all 
GMP-grade from Lonza). At day 0 of the MLTC, human 
recombinant IL-4 (5 ng/ml, Cellgenix) was added. Human 
recombinant IL-2 (Aldesleukin, Novartis) was added start-
ing at day 2 (150  IU/ml) and every 2–3  days, half of the 
culture medium was refreshed with T cell medium contain-
ing IL-2. The T cells were weekly counted and restimulated 
using irradiated autologous tumor cells. After 4 weeks of 
culture, the T cell batches were tested for reactivity against 
the tumor by overnight stimulation of T cells with tumor 
cells. Thereafter, culture supernatant of the co-cultures was 
collected and stored at −20 °C until further use, and the T 
cells were stained for flowcytometric analysis. The IFNγ 
concentration in the culture supernatant was quantified by 
ELISA (Sanquin).
In some experiments,  CD4+ T cells were depleted from 
the PBMC at the start of MLTC, or  CD25+ cells were 
depleted from the cultured T cells at week 2 of the MLTC. 
Depletion of either  CD4+ or  CD25+ cells was done by 
MACS using CD4 or CD25 human microbeads (Miltenyi 
Biotec GmbH), followed by MACS separation according to 
the manufacturer’s recommendations using either LD col-
umns (CD4) or LS columns (CD25).
To investigate the role of IDO in the induction of tumor-
reactive T cells, the IDO inhibitor 1-methyl-tryptophan 
(1-MT) was added to several MLTC. Two different iso-
forms of 1-MT, 1-MT-L, and 1-MT-D (both from Sigma 
Aldrich), were used, both in a concentration of 150  µM. 
Also, l-tryptophan (150  μM; Sigma Aldrich) was added 
in some cultures, to control for the tryptophan depletion 
caused by IDO (due to low cell numbers, we were only able 
to test this for four tumor cell lines).
Short inhibition assay
To test the capacity of the tumor cell lines to inhibit T cell 
activation and proliferation, a short inhibition assay was set 
up. PHA-stimulated (0.5  μg/ml), allogeneic PBMC were 
co-cultured with tumor cells in various ratios. In addi-
tion, the capacity of tumor-derived cell culture superna-
tants (TSN) to inhibit PBMC activation was investigated. 
To this end, tumor cells were plated in similar concen-
trations as was done for the co-culture. After 24  h, TSN 
was collected and added to PHA-stimulated PBMC. T 
cell activation was analyzed after 48  h by flowcytometric 
analysis for CD25 expression and by measuring the IFNγ 
concentration in the TSN. Using these data, the inhibition 
index was calculated using the formula: 100  −  (%CD25+ 
[PBMC:tumor]/%CD25+ [PBMC]  ×  100). For assess-
ment of proliferation, PBMC were stimulated in the 
presence of tumor cells for 5 days and at day 4 3[H]-thy-
midine was added to the co-culture. Incorporation of 3[H]-
thymidine was measured 16  h later. Some experiments 
were performed in the presence of the lectin-inhibitor 
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Fig. 1  Accumulation of  CD4+CD25hiFoxP3+ T cells during MLTC. 
a  CD4+CD25hiFoxP3+ T cell frequencies depicted as percentage of 
 CD3+ T cells in the PBMC that were used for generation of T cells 
in the MLTC (PBMC) as well as in the T cell batch that was gen-
erated in 4  weeks (CTL). #T cell batch that was used for depletion 
of  CD25+ cells in e. b Representative plots of the flow cytomet-
ric analysis of  CD4+CD25hiFoxP3+ T cells during the MLTC. c 
 CD4+CD25hiFoxP3+ T cell frequencies (depicted as percentage 
of  CD3+ T cells) peak at day 14 during the MLTC. Differences in 
 CD4+CD25hiFoxP3+ T cell frequencies were statistically analyzed 
by a one-way ANOVA with Tukey post hoc comparisons; *p < 0.05 
and **p < 0.01. d Expansion factors of T cells generated in differ-
ent MLTC and the frequencies of  CD4+CD25hiFoxP3+ T cells in the 
same MLTC at day 14. f IFNγ concentrations in the culture superna-
tant after overnight stimulation of the T cell batch with autologous 
tumor cells. Mean data with standard deviation of one experiment 
performed in triplo are shown
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N-acetyl-d-lactosamine (5 mM) (LacNAc; Sigma Aldrich), 
that blocks the activity of galectins.
Flowcytometry
After incubation with LIVE/DEAD® Fixable Yellow Dead 
Cell Stain (Molecular probes, Life Technologies), the cells 
that were tested for reactivity against the autologous tumor 
cell line were stained with CD3-V450, CD4-FITC, CD8-
APCCy7, CD137-APC, CD154-PECF495, IFNγ-Alexa 
Fluor700, and IL-2-PE [where appropriate Brefeldin-A 
(10 µg/ml, Sigma Aldrich)] and were added to the cultures 
to perform intracellular staining. For assessment of regula-
tory T cell frequencies in the T cell batches, the cells were 
stained with CD3-V500, CD4-AlexaFluor700, CD8-FITC, 
CD25-PECy7, and FoxP3-PECF594 in combination with 
the Treg fixation/permeabilization kit (BD Biosciences). 
The activation of T cells in the short inhibition assay was 
determined by staining with CD3-Pacific Blue, CD8-PE, 
CD4-Alexa Fluor700, and CD25-PECy7. Tumor cells were 
assayed for galectin-3 expression by staining with galectin-
3-Alexa Fluor647. All antibodies used for flowcytmetric 
analyses were from BD Biosciences (San Diego, USA). All 
flowcytometric analyses were performed using a BDLSR-
Fortessa (BD Biosciences) and data analysis was done 
using FlowJo software (FlowJo, LLC).
Analysis of IDO expression and enzymatic activity
For analysis of IDO expression and activity, irradiated 
tumor cells were cultured for 48 h in the absence and pres-
ence of 150  IU/ml IFNγ. Thereafter, the supernatant was 
collected and stored at −20 °C and the cells were har-
vested; the cell pellet was snap frozen and stored at −80 °C 
until further use. mRNA was extracted from the frozen 
cell pellets using the RNeasy plus mini kit (Qiagen N.V.) 
and cDNA was synthesized with the High capacity RNA-
to-cDNA kit (Life Technologies Europe BV). RT-qPCR 
analysis of IDO expression (primerset tcatctcacagaccacaa/ 
gcagtaaggaacagcaata) was performed using IQ SYBR 
Green supermix (BioRad) on a CFX96 real-Time PCR 
detection system (Biorad). All RT-qPCR data were normal-
ized to GAPDH (primerset gtgctgagtatgtcgtggagtctac/gg
cggagatgatgacccttttgg) expression and analyzed using the 
delta-Ct method. In the culture supernatant, the concen-
tration of kynurenine was measured as an indicator for the 
enzymatic activity of IDO as described before [32].
Depletion of galectin-3 from TSN
To assess specifically the role of tumor-derived galectin-3 
in the inhibition of T cell activation by tumor cells, we 
depleted galectin-3 from TSN that was used for the short 
inhibition assay. To this end, ELISA plates were coated 
with anti-galectin-3 antibodies (Peprotech). TSN was added 
to the coated ELISA plates and galectin-3 was depleted by 
serial incubation (4×) of the TSN in anti-galectin-3 coated 
wells for 2 h per incubation step. The efficiency of deple-
tion was tested by a galectin-3 ELISA according to the 
manufacturers’ recommendations (Peprotech).
Generation of galectin-3 knock-out cell lines using 
CRISPR/Cas9 genome editing
Cloning of the Cas9 target sequence was performed based 
on PCR and Gibson assembly (In-Fusion kit, Clontech 
Laboratories Inc.). Cells were transfected with a CRISPR-
Cas9 construct targeting exon 3 of the human galectin-3 
gene. Transfections were performed using  Lipofectamine® 
2000 (Thermofisher Scientific) according to manufacturers’ 
recommendations. Transfected cells were tested for surface 
expression as well as secretion of galectin-3.
Results
Accumulation of  CD4+CD25hiFoxP3+ T cells 
during culture is associated with low T cell expansion
Tumor-reactive T cell batches were generated in MLTC by 
weekly stimulation of PBMC with autologous tumor cells. 
Sufficient cell numbers for infusion could be reached after 
one MLTC of 4  weeks for some patients, while for oth-
ers multiple MLTC were needed to reach the required cell 
numbers for infusion. The expansion rates of T cells were 
highest in the second half of the MLTC (week 2–week 4). 
Analysis of the T cell batches that were infused into the 
Fig. 2  Depletion strategies to eliminate  CD4+CD25hiFoxP3+ T 
cells from MLTC. a, b  CD4+CD25hiFoxP3+ T cells were depleted 
at week 2 of MLTC using MACS separation and CD25 microbeads. 
The T cells were weekly counted to calculate the expansion factor. 
Tumor reactivity was tested by overnight stimulation of the T cells 
at week 4 of MLTC with autologous tumor cells. CD137 expression 
was used to identify the tumor-reactive  CD4+ and  CD8+ T cells. The 
absolute number of tumor-reactive T cells was calculated with the 
expansion factor of the MLTC. a Example of  CD4+CD25hiFoxP3+ T 
cell depletion in which specifically the  CD25hi T cells were depleted 
(left panel), resulting in increased expansion of T cells in the MLTC 
(middle panel) and increased numbers of  CD8+ tumor-reactive T cells 
(right panel). b Example of depletion in which not only the  CD25hi 
T cells but also the  CD25+ activated T cells were depleted from the 
MLTC (left panel), resulting in decreased expansion of T cells (mid-
dle panel) and decreased numbers of tumor-reactive T cells (right 
panel). c Expansion factors (upper row) and numbers of tumor-reac-
tive T cells (lower row) in MLTC with CD4-depleted PBMC. d The 
number of tumor-reactive  CD8+ T cells at week 4 of 6 independent 
MLTC that were started with CD4-depleted PBMC compared to non-
depleted PBMC (control)
◂
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patients in our ongoing clinical protocol [5] showed that 
they contain  CD4+CD25hiFoxP3+ T cells (Supplementary 
Figure S1a). Importantly, while there were no overt dif-
ferences between the frequencies of  CD4+CD25hiFoxP3+ 
T cells in the PBMC used for MLTC, it became clear that 
higher frequencies of these cells were observed after the 
MLTC culture period in T cell batches used for treatment 
of non-responder patients (Fig.  1a). This suggests that 
the relatively high frequencies of  CD4+CD25hiFoxP3+ T 
cells observed in 3 out of 5 infusion products from non-
responders accumulated during culture. Subsequently, 
the expansion of  CD4+CD25hiFoxP3+ T cells was ana-
lyzed during the MLTC cultures. There was a peak in 
 CD4+CD25hiFoxP3+ T cells frequency at day 14 of the 
MLTC (Fig.  1b, c), and there was a direct inverse cor-
relation between  CD4+CD25hiFoxP3+ T cell frequen-
cies and the final expansion of T cells at the end of the 
MLTC (Spearman’s rho, r  =  −0.700, p = 0.04) (Fig.  1d). 
Since we previously found that the expansion of tumor-
specific T cells became visible after 2  weeks of culture, 
our data suggested that the presence of high numbers of 
 CD4+CD25hiFoxP3+ T cells at this time point had a nega-
tive impact on overall T cell proliferation.
To functionally assess if the co-expanded 
 CD4+CD25hiFoxP3+ T cells were responsible for the 
low expansion capacity of tumor-specific T cells, we first 
depleted the  CD4+CD25hiFoxP3+ T cells from a T cell 
infusion product from a non-responder patient with a high 
 CD4+CD25hiFoxP3+ T cell frequency and compared the 
proliferation of the  CD4+CD25hiFoxP3+ T cell-depleted T 
cell batch to the non-CD4+CD25hiFoxP3+ T cell-depleted 
T cells during MLTC.  CD4+CD25hiFoxP3+ T cell deple-
tion resulted in increased proliferation (Fig. 1e) and tumor-
specific IFNγ secretion (Fig. 1f) of the T cells, indicating 
that the  CD4+CD25hiFoxP3+ T cells were capable of sup-
pressing the expansion of tumor-reactive T cells. Based 
on this result, a series of experiments was performed to 
improve the expansion of T cells in the MLTC by elimina-
tion of  CD4+CD25hiFoxP3+ T cells at week 2 of the MLTC 
using a GMP-compliant MACS procedure for CD25-deple-
tion. Only when this procedure resulted in the selective 
depletion of  CD25hi cells (Fig. 2a, left panel), it was associ-
ated with an improved expansion of T cells (Fig. 2a, middle 
panel), and an increased number of  CD8+ tumor-reactive 
cells (Fig. 2a, right panel), similar to our initial experiment. 
However, in cases where this method not only led to the 
depletion of  CD25hi T cells but also in that of  CD25+ effec-
tor T cells (Fig. 2b, left panel), the CD25-depleted fraction 
hardly expanded and lower numbers of  CD8+ tumor-reac-
tive cells were detected (Fig. 2b, middle and right panel). 
We repeated this protocol eight times using autologous 
PBMC and tumor cells from several patients but the vari-
ability in outcome remained and apparently was associ-
ated with the quality of the separation between  CD25hi T 
cells and  CD25+ T effector cells. If only  CD25hi T cells and 
not  CD25+ T effector cells were depleted, it resulted in an 
improved expansion of tumor-reactive T cells in three out 
of four experiments (Supplementary Figure S1b). As an 
alternative for the depletion of  CD4+CD25hiFoxP3+ T cells, 
we depleted the complete  CD4+ fraction from the PBMC at 
the start of the MLTC (Supplementary Figure S2).  CD4+ 
T cell depletion was very consistent and almost complete, 
although low numbers of  CD4+ T cells were still detectable 
during the culture. Although  CD4+ T cell depletion did not 
always result in increased expansion rates of the T cells 
(Fig. 2c, upper panels), the number of tumor-reactive  CD8+ 
T cells was often increased (Fig. 2c, lower panels). In four 
out of six MLTC using the PBMC and melanoma cells 
of different patients,  CD4+ T cell depletion increased the 
absolute number of tumor-reactive  CD8+ T cells obtained 
after 4 weeks of MLTC. However, the opposite effect was 
observed for the two other MLTC (Fig.  2d). Hence, also 
 CD4+ T cell depletion does not guarantee a more pro-
nounced expansion of tumor-specific  CD8+ T cells.
In conclusion, the presence of high percentages of 
 CD4+CD25hiFoxP3+ T cells in the MLTC cultures sup-
presses the capacity of tumor-reactive T cells to proliferate 
upon stimulation with autologous tumor cells, but the spe-
cific depletion of  CD4+CD25hiFoxP3+ T cells using fully 
GMP-compliant procedures and CD25-specific or CD4-
specific antibodies is not robust enough to guarantee good 
tumor-reactive T cell expansions during MLTC.
Tumor cell intrinsic factors inhibit the activation 
and proliferation of PBMC
To examine the T cell suppressive capacity of melanoma 
tumor cell lines, we set up a short assay in which we exam-
ined the activation of T cells in the presence of increasing 
numbers of tumor cells. When we used tumor cells derived 
from a patient whose PBMC displayed a low expansion 
capacity in the MLTC, we observed decreased expression 
Fig. 3  Tumor cells show inhibitory capacity in short inhibition 
assay. a Flow cytometric analysis of CD25 expression on T cells 
within PBMC stimulated with PHA for 48  h at different ratios of 
PBMC:tumor cells ratios. b IFNγ concentrations present in the cell 
culture supernatant of the short inhibition assay. c Proliferation as 
measured by 3[H]-thymidine incorporation after 5  days of culture 
in the short inhibition assay. Inhibition index at the 1:0.5 PBMC to 
tumor cell ratio (d) or in presence of tumor cell supernatants (e). f, 
g Correlation between inhibition index at 1:0.5 PBMC to tumor cell 
ratio and the expansion factors at week 4 of the MLTC, using Spear-
man’s rho correlation. h, i The inhibition index at 1:0.5 PBMC 
to tumor cell ratio for the clinical responder and non-responder 
patients. Differences were statistically analyzed with the non-par-
ametric Mann–Whitney U test. Inhibition index = 100  −  (%CD25+ 
[PBMC:tumor]/%CD25+ [PBMC] × 100)
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of the activation marker CD25 on T cells (Fig. 3a), lower 
concentrations of IFNγ in the culture supernatant (Fig. 3b) 
and decreased proliferation of PBMC with increasing 
tumor cell concentrations (Fig. 3c). A large variation was 
observed between different tumor cell lines in their capac-
ity to inhibit T cell activation (Fig. 3d). To test whether the 
inhibition exerted by tumor cells was contact dependent, 
we repeated the experiments with tumor cell supernatants 
(TSN) showing that T cell activation was also inhibited 
by TSN. Although the inhibitory capacity varied between 
the TSN of different tumor cell lines (Fig. 3e), our results 
indicate that tumor-induced inhibition of T cell activation is 
dependent on soluble factors.
To analyze the predictive value of the short inhibi-
tion assay for the capacity of a tumor cell line to effec-
tively induce T cell expansion in the MLTC, we plot-
ted the inhibitory capacity against the expansion index at 
week 4 of the MLTC (Fig.  3f, g). A negative correlation 
exists between the inhibitory capacity and the expansion 
of T cells in the MLTC, irrespective of whether inhibition 
was caused by the tumor cells or TSN (Spearman’s rho, 
r = −0.57, p < 0.05 and r = −0.54, p < 0.05 respectively). 
Interestingly, when we compared the inhibitory capacity 
of the tumor cells and TSN of the responder patients and 
the non-responder patients, it was clear that the tumor cells 
that were derived from non-responder patients showed a 
much higher inhibitory capacity than those derived from 
responder patients (Fig. 3h, i). The inconsistency between 
the experiments performed with tumor cells and with TSN 
might be the result of differences in metabolic activity of 
tumor cells during the experiments, which could be the 
result of differences in cell–cell interactions between the 
two conditions. Unfortunately, we could not include all ten 
patients (five responders and five non-responders) in these 
experiments, since not all tumor cells were available in 
sufficient quantities. These data not only indicate that the 
outcomes of the short inhibition assay reflect the ability of 
tumor cells to induce expansion of tumor-specific T cells 
in a MLTC but also that tumor cells suppress the activa-
tion and expansion of autologous tumor-specific T cells via 
soluble mediators.
Inhibition of IDO increases the activation 
and expansion of tumor-specific T cells in a MLTC
One of the mechanisms underlying the suppression of T 
cell activation and expansion by soluble mediators might be 
IDO-induced tryptophan starvation [23]. Analysis of IDO 
mRNA expression by RT-qPCR showed that all cell lines 
expressed IDO, and that for most cell lines, this expres-
sion was increased upon stimulation with IFNγ for 48  h. 
There were substantial differences in the level of upregu-
lation between the tested tumor cell lines. Importantly, the 
IFNγ-induced expression of IDO by tumor cell lines was 
inversely correlated with the expansion rate of T cells in 
the corresponding MLTC (Fig. 4a, left panel) and directly 
associated with the capacity of a tumor cell line to inhibit 
activation of T cells (Fig. 4a, right panel). To test whether 
IDO was involved in this suppression we used the two iso-
forms of the IDO inhibitor 1-MT (1-MT-D and 1-MT-L). 
Both isoforms successfully inhibited IDO activity as meas-
ured by a decreased kynurenine concentration (Supplemen-
tary Figure S3a) and partly restored the tumor cell induced 
inhibition of T cell activation (Fig. 4b). Although 1-MT-L 
had a stronger effect on the kynurenine levels than 1-MT-
D, our data suggest that the latter was better with respect 
to the expansion of activated T cells in the MLTC (Sup-
plementary Figure S3b). To compensate for the lower anti-
kynurenine effect of 1-MT-D, we added this compound 
three times per week to the MLTC cultures and showed that 
this was more effective than adding 1-MT-D only once a 
week (Fig. 4c, d). For five out of six tumor cell lines, the 
addition of 1-MT-D 3 times per week improved the prolif-
eration rate of the T cell batch, whereas addition of l-tryp-
tophan improved the T cell proliferation in three out of four 
experiments (Supplementary Figure S3c) and as a result in 
increased numbers of tumor-reactive T cells for four out 
of six tumor cell lines (Fig. 4e, f). The increase of tumor-
reactive cells was observed in both the  CD4+ T cell and/
or the  CD8+ T cell populations (Fig. 4g, h). Not only the 
number of tumor-reactive T cells was increased but also the 
percentage of polyfunctional T cells producing the inflam-
matory cytokines IFNγ and IL-2 was increased (Supple-
mentary Figure S3d). We concluded that inhibition of IDO 
by 1-MT-D can improve the activation and expansion of 
tumor-reactive T cells against melanoma in MLTC.
Tumor cell-derived galectin-3 inhibits the activation 
of T cells
The soluble factor galectin-3 might play a role by tumor-
induced suppression of T cell activation. Analysis of galec-
tin-3 secretion by ELISA showed that most tested tumor 
cell lines produced galectin-3 to variable amounts (Fig. 5a). 
The level of galectin-3 secretion was negatively correlated 
with the final expansion factor of the T cells at the end of 
the MLTC performed with these tumor cells (Fig. 5a). To 
study whether galectin-3 inhibited T cell activation, the 
lectin-inhibitor LacNAc was added in the short inhibition 
assay. This significantly reversed the tumor-induced inhibi-
tion of T cell activation (Fig. 5b), but the effects were not 
dramatic which might be attributed to the fact that Lac-
NAc itself also hampers T cell activation (Supplementary 
Figure S4). In addition, LacNAc can also inhibit other 
galectins, including the immunosuppressive galectin-1. To 
specifically address the role of galectin-3 and to prevent 
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Fig. 4  Inhibition of IDO expansion potential in MLTC. a IFNγ-
induced mRNA expression of IDO by tumor cell lines was assessed 
by qPCR. IDO expression was plotted together with the expansion 
factor of the T cells in the MLTC with the same tumor cells (left 
panel) as well as with the inhibition index of the tumor cell line in 
the short inhibition assay at a 1:0.5 PBMC to tumor cell ratio (right 
panel). The correlation was calculated with Spearman’s rho correla-
tion analysis. b The percentage of  CD25+ activated T cells when two 
isoforms of the IDO inhibitor 1-MT were added to the short inhibi-
tion assay. c T cell counts of the MLTC to which 1-MT-D was added 
once or three times per week. d Increase in cell counts at week 4 of 
the MLTC after addition of 1-MT-D once or three times per week 
compared to without addition of 1-MT-D. Mean relative cell counts 
with SD for six different tumor cell lines (student’s T test). e Increase 
in the number of  CD137+ expressing tumor-reactive T cells after 
overnight stimulation with the autologous tumor cell line at week 4 of 
the MLTC performed with addition of 1-MT-D, either once or three 
times per week. Tumor line 08.02 performed so badly in the MLTC 
that not enough T cell were generated to perform the reactivity test. 
f Fold-change in tumor-reactive  CD3+CD137+ T cell counts at week 
4 of the MLTC with1-MT-D once or three times per week over no 
1-MT-D control. Mean relative cell counts with SD for five differ-
ent tumor cell lines (student’s T test). The increase in tumor-reactive 
 (CD137+) cell counts as shown in (E) for  CD4+ T cells (g) and  CD8+ 
T cells (h)
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the intrinsic immunomodulating activity of LacNAc, we 
depleted galectin-3 from the TSN and compared T cell 
activation in cultures where either galectin-3 depleted or 
control TSN was used. Depletion of galectin-3 almost 
completely alleviated the inhibition of T cell activation by 
TSN (Fig. 5c, d). Finally, we knocked out galectin-3 from 
a tumor cell line using CRISPR/Cas9 technology. Again, 
less inhibition of T cell activation was found for the cell 
line lacking galectin-3 (Fig. 5e). To validate these findings, 
we used the galectin-3 knock-out cell line to induce tumor-
reactive T cells in a MLTC, and this resulted in a marked 
increase in the expansion of T cells (Fig.  5f), and also a 
significant increase of IFNγ secretion by tumor-reactive 
T cells after stimulation with the autologous tumor cells 
(Fig.  5g) and an increased frequency of tumor-specific 
 CD8+ T cells (Fig. 5h).
Discussion
Mixed lymphocyte tumor cell cultures (MLTC) can be very 
efficient for the generation of high numbers of tumor-spe-
cific T cells to treat melanoma patients with adoptive cell 
transfer [5, 6, 33]. In selected cultures, these T cell batches 
were shown to contain high frequencies of neoepitope-
specific T cells, selectively recognizing autologous tumor 
cells but not HLA-matched melanoma cell lines or known 
shared antigens [6, 7]. However, not for every patient the 
expansion of tumor-specific T cells using MLTC is suc-
cessful and our experiments show that at least three factors, 
i.e., increased frequencies of  CD4+CD25hiFoxP3+ T cells, 
the production of IDO, and the production of galectin-3 by 
the tumor cells, play a role in this hampered expansion of 
tumor-specific T cells.
We found that the presence of  CD4+CD25hiFoxP3+ T 
cells, which accumulate during culture, can suppress the 
expansion of tumor-reactive T cells. A clear induction of 
 CD4+CD25hiFoxP3+ T cells during culture with a peak at 
week 2 was associated with impaired expansion of the T 
cell batch and, therefore, we chose to deplete these culture-
induced  CD4+CD25hiFoxP3+ T cells, a population which 
may contain both activated effector T cells and suppressive 
T cells, at this point of the MLTC. However, MACS tech-
nology, which is the only GMP-grade technology that is 
currently available for separating cell populations, was not 
sensitive enough to distinguish between  CD25+effector T 
cells and the immunosuppressive cells that are more abun-
dant in the  CD25hi population. Different results might be 
obtained when  CD4+CD25hiFoxP3+ T cells are depleted 
at the start of the culture, as was shown by Li et al. [27]. 
Since we had no evidence for the presence of large num-
bers of  CD4+CD25hiFoxP3+ T cells in PBMC at the start 
of the culture, we did not perform depletion studies at this 
point. However, the observation that depletion of  CD4+ T 
cells at the start of the MLTC enhanced the generation of 
tumor-specific  CD8+ T cells indicates that prevention of 
 CD4+CD25hiFoxP3+ T cell accumulation is beneficial for 
an efficient MLTC. However, in view of the fact that  CD4+ 
T cells play a crucial role in optimal tumor-specific CTL 
activity [34, 35] and are themselves capable of recognizing 
and controlling melanoma [6, 36–39], it seems unwise to 
prevent potential  CD4+CD25hiFoxP3+ T cell accumulation 
at the cost of tumor-specific  CD4+ T cells.
To investigate the role of immunomodulatory mol-
ecules expressed by the tumor cells, we used a short 
inhibition assay of which we showed that it could pre-
dict the expansion of tumor-specific T cells in a MLTC. 
We showed that IDO negatively affects the expansion 
of tumor-reactive T cells and that this could be reversed 
by the IDO inhibitor 1-MT-D and to a lesser extent by 
1-MT-L. To unravel whether the suppressive effect of 
IDO is mediated via depletion of tryptophan or forma-
tion of toxic metabolites like kynurenin, the effect of 
tryptophan addition was studied. In contrast to IDO 
inhibition by 1-MT-D, the addition of tryptophan did 
not improve expansion of tumor-specific T cells in all 
cases, suggesting that the detrimental effect of IDO on 
tumor-specific T cell expansion was not merely medi-
ated by tryptophan depletion. In melanoma, the expres-
sion of IDO by the tumor has been associated with 
impaired survival [10] and expression of IDO by cir-
culating immune cells was described to be increased 
with advanced disease stage in melanoma patients [40]. 
The two isomers of 1-MT, 1-MT-D and 1-MT-L, have 
Fig. 5  Galectin-3-mediated tumor cell induced T cell inhibition. 
a Comparison of the expansion factor of T cells at week 4 of the 
MLTC and the galectin-3 secretion in 48 h supernatant of the tumor 
cell lines used. b The percentage of  CD25+ activated T cells in the 
short inhibition assay with or without the galectin-3 inhibitor Lac-
NAc (5  mM). The difference between the conditions was analyzed 
using a one-way ANOVA with a Tukey post hoc test. c  CD25+ acti-
vated T cells in the short inhibition assay performed with galectin-3 
depleted TSN compared to non-depleted control TSN. Mean with 
SD for 4 different tumor cell lines (two-way ANOVA with multiple 
comparisons; **p < 0.01 and ***p < 0.001). d The inhibition index at 
a 1:0.5 PBMC to tumor cell ratio of the control condition compared 
to the galectin-3-depleted TSN (unpaired T test). e  CD25+ activated 
T cells in the short inhibition assay performed with a galectin-3 
knout-out tumor cell line compared to the wild-type tumor cell line 
(paired T test). f Expansion factors of T cells that were induced in an 
MLTC with autologous wild-type tumor cells and galectin-3 knock-
out tumor cells. g IFNγ concentrations in the culture supernatant 
after overnight stimulation with autologous tumor cells of the T cell 
batches generated against the wild-type melanoma cells (white bars) 
and against the galectin-3 knock-out melanoma cells (black bars). T 
cell was stimulated with both the wild-type and galectin-3 knock-out 
tumor cells, as depicted on the x-axis. h Frequencies of tumor-spe-
cific  (CD137+)  CD8+ T cells in T cell batch after overnight stimula-
tion with autologous tumor cells
◂
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a potentially different activity which is dependent on 
the biological context of IDO expression [41–43]. In 
our MLTC system, 1-MT-D was superior over 1-MT-L. 
Moreover, 1-MT-D already showed anti-tumor activity 
in a mouse model of transplantable melanoma [43] and 
is currently under clinical development for the treatment 
of different cancer types [41]. Moreover, the develop-
ment of IDO inhibitors has been placed on the priority 
list of immunotherapeutic agents by the National Cancer 
Institute [44], which is important because IDO should 
also be blocked in vivo where it is locally produced in the 
tumor-microenvironment.
We also identified galectin-3 as a tumor-derived fac-
tor hampering the generation of tumor-reactive T cells in 
a MLTC. Galectin-3 regulates T cell function by several 
mechanisms [20], among others by negative regulation 
of the TCR-mediated T cell response [19]. Interfering 
with galectin-3 binding to tumor infiltrating lympho-
cytes (TIL) boosted the cytotoxicity of these TIL [16]. 
The use of galectin-3-depleted tumor supernatants and 
the use of a galectin-3 knock-out tumor line enabled us 
to specifically eliminate tumor-derived galectin-3 in our 
culture system. Despite the fact that T cells might also 
produce galectin-3, elimination of tumor-derived galec-
tin-3 resulted in improved expansion of tumor-reactive 
T cells, indicating an important role for the galectin-3 
produced by the tumor in the suppression of T cell acti-
vation. Galectin inhibitors are currently developed for 
clinical application [45, 46], and maybe extremely useful 
for both in- and ex  vivo applications to boost the anti-
tumor response, especially since these inhibitors can also 
abrogate the potential immunosuppressive effect of other 
galectins (e.g., galectin-1) secreted by tumor cells [47].
We conclude that the induction of  CD4+CD25hiFoxP3+ 
T cells and the expression of IDO and galectin-3 by mela-
noma cells are undesirable for a good expansion of tumor-
reactive T cells in a MLTC. Although  CD4+CD25hiFoxP3+ 
T cell depletion strategies turned out not to be robust 
enough to allow implementation into a clinical protocol 
aiming at improved generation of tumor-reactive T cells, 
inhibition of IDO and galectin-3 proved to be successful. 
The tumor-derived suppressive mechanisms that we found 
to be negatively regulating the ex vivo expansion of tumor-
reactive T cells are probably not limited to MLTC but ham-
per T cell reactivity in the tumor-microenvironment in vivo 
as well. Therefore our findings could have an impact on the 
therapeutic potential of other adoptive T cell transfer and 
immunotherapeutic protocols and may lead to a more suc-
cessful treatment of metastatic melanoma patients.
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